Nyxoah’s Genio® Wins Prix Galien UK 2026 Award for Best Medical Technology

Nyxoah’s Genio hypoglossal nerve stimulation therapy won the Prix Galien UK 2026 Award for Best Medical Technology. The award recognizes Genio’s contribution to treating Obstructive Sleep Apnea, a condition affecting millions and linked to cardiovascular risks. CEO Olivier Taelman highlighted the collective effort of engineers, clinicians, and patients, noting the award reflects growing adoption in the UK alongside NHS and private partners. This recognition coincides with significant commercial momentum, including recent FDA approval, U.S.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.